InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 365 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare InMed Pharmaceuticals to related businesses based on the strength of its dividends, institutional ownership, valuation, profitability, risk, earnings and analyst recommendations. Insider & Institutional Ownership 23.2% of shares […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 361 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare InMed Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation. Earnings and Valuation This table compares InMed […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 362 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare InMed Pharmaceuticals to similar companies based on the strength of its earnings, analyst recommendations, dividends, valuation, institutional ownership, risk and profitability. Profitability This table compares InMed Pharmaceuticals and […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Get Rating) is one of 462 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare InMed Pharmaceuticals to similar businesses based on the strength of its earnings, dividends, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares InMed Pharmaceuticals and […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Get Rating) is one of 347 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare InMed Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, institutional ownership and profitability. Insider & Institutional Ownership 24.7% of shares […]